CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation("CEL SCI" or the "Company") today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. In the month of December it enrolled 33 patients. Total patient enrollment for the trial is now 668 as of December 31, 2015 in the world's largest Phase 3 study in head and neck cancer.
View full press release